STING1 and neoplasm: In triple-negative breast cancer therapy, the PARP inhibitor olaparib induced T-cell infiltration via the cGAS/STING pathway in tumor and paracrine activation of DCs was enhanced in the process; furthermore, activation of the pathway was more obvious in homologous recombination-deficient tumor cells (Pantelidou et al., 2019).